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Photodynamic therapyMacrophages play key roles in inﬂammatory disorders. Therefore, they are targets of treatments aiming at
their local destruction in inﬂammation sites. However, injection of low molecular mass therapeutics,
including photosensitizers, in inﬂamed joints results in their rapid efﬂux out of the joints, and poor
therapeutic index. To improve selective uptake and increase retention of therapeutics in inﬂamed tissues,
hydrophilic nanogels based on chitosan, of which surface was decorated with hyaluronate and which were
loaded with one of three different anionic photosensitizers were developed. Optimal uptake of these
functionalized nanogels by murine RAW 264.7 or human THP-1 macrophages as models was achieved after
b4 h incubation, whereas only negligible uptake by murine ﬁbroblasts used as control cells was observed.
The uptake by cells and the intracellular localization of the photosensitizers, of the ﬂuorescein-tagged
chitosan and of the rhodamine-tagged hyaluronate were conﬁrmed by ﬂuorescence microscopy.
Photodynamic experiments revealed good cell photocytotoxicity of the photosensitizers entrapped in the
nanogels. In a mouse model of rheumatoid arthritis, injection of free photosensitizers resulted in their rapid
clearance from the joints, while nanogel-encapsulated photosensitizers were retained in the inﬂamed joints
over a longer period of time. The photodynamic treatment of the inﬂamed joints resulted in a reduction of
inﬂammation comparable to a standard corticoid treatment. Thus, hyaluronate–chitosan nanogels
encapsulating therapeutic agents are promising materials for the targeted delivery to macrophages and
long-term retention of therapeutics in leaky inﬂamed articular joints.-2-phenylindolylhydrochloride;
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Recently developed approaches for the treatment of various
diseases rely on encapsulation strategies to deliver therapeutic
molecules to deﬁned cells or tissues. These strategies involve eitherthe covalent attachment of therapeutic agents to macromolecules or
their entrapment by non-covalent interactions with the materials
assembling into nanostructure. In both approaches, issues are to
achieve deﬁned localization of these nanodevices into living tissue
and the controlled release from the nanodevices of the therapeutic
agents in order to achieve therapeutic efﬁcacy with minimal side
effects. Macrophages are responsible of the increased vascular and
tissue permeability observed at sites of inﬂammation, including in
inﬂamed articular joints in pathologies such as rheumatoid arthritis
[1–3], suggesting that their selective elimination may be beneﬁcial for
the treatment of inﬂammatory disorders. Thus, therapeutic protocols
targeting macrophages may open new routes for the treatment of a
wide range of diseases. Photodynamic therapy (PDT) is a modality of
treatment already used in clinic for treating human diseases [4–7],
including rheumatoid arthritis [8]. PDT involves a nontoxic photo-
activable dye called a photosensitizer (PS) in combination with
harmless visible light of deﬁned wavelength, which excites the PS to a
high energy triplet state. When excited, the PS reacts with cellular
Fig. 1. Chemical structures of the photosensitizers. A. Tetra-phenyl-porphyrin-tetra-
sulfonate (TPPS4). B. Tetra-phenyl-chlorin-tetra-carboxylic acid (TPCC4). C. Chlorin
e6 (Ce6).
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oxygen and oxygen radicals, which oxidize cellular nucleic, fatty and
amino acids, and ultimately induce cell death. Several studies on
animal models of rheumatoid arthritis using the photosensitizers
photofrin, BPDMA, mTHPC or hexyl ester of 5-aminolevulinic acid
have shown the beneﬁt of PDT approaches [8–14]. However, one
major problem of photodynamic therapy of inﬂamed tissues is the
enhanced permeability resulting from inﬂammation and leakage of
the therapeutics. This leakage could be avoided by the immobilization
of the photosensitizers in a device that allows the photosensitizers to
be targeted and retained in a deﬁned body tissue. In this context,
nanosized polymeric composites/carriers may be of interest. Several
strategies involving nanosized carriers for photosensitizer delivery
such as liposomes, polymeric micelles, metal-based or silica-based
nanoparticles have already been explored [15–18]. The preparation of
chitosan-based hydrophilic nanogels has beenwidely described in the
literature, employing penta sodium triphosphate (PSTP) as the
complexing anionic molecule for the polycation chitosan [19–25].
Chitosan-based nanogels have been studied as carriers of oligonu-
cleotides in gene therapy, for mucosal vaccination, in tissue
engineering or drug delivery [26–28]. However, highly positive
nanoparticles are generally cytotoxic, or are unselectively taken up
by cells due to their positive charge, suggesting that developing
negative chitosan-based nanogels could be of biological interest.
Nanogels based on a chitosan core matrix decorated on their surface
with polyanions have been described [28,29].
We hypothesized that photosensitizers encapsulated in biocom-
patible polymers may reside longer in the joints and may achieve
more efﬁcient PDT. In addition, the encapsulation of photosensitizers
in hyaluronate-decorated nanogels targetingmacrophages would also
improve selectivity of the process. In the present study, three different
anionic photosensitizers, i.e. tetra-phenyl-porphyrin-tetra-sulfonate
(TPPS4), tetra-phenyl-chlorin-tetra-carboxylate (TPCC4) and chlorin
e6 (Ce6) (Fig. 1), were incorporated into hyaluronate-decorated
chitosan-based nanogels.
These nanogels were studied as macrophage-targeting phototoxic
materials for photodynamic therapy and in an in vivo study in mice
using the antigen-induced arthritis (AIA) model of rheumatoid
arthritis (RA) which recapitulates features of human RA.
2. Materials and methods
2.1. Nanogel formulation
Nanogels [30] were prepared by adding 10 mL of a 0.1% w/w penta
sodium triphosphate solution (TPP, aka tripolyphosphate, Sigma-
Aldrich, Steinheim, Germany) to 90 mL of a 0.1% w/w chitosan (low
viscosity chitosan from Primex, Iceland, in-house puriﬁed by ﬁltration
through a 0.1 μm pore size hydrophilic ﬁlter (Minisart hydrophilic
cellulose acetate, Sartorius, Germany)) or ﬂuorescein-tagged (cf below)
chitosan solution at pH 3.0 under constant stirring and by slow drop-
wise addition. The pHwasmaintained at pH3.0 byadding0.1 NHCl. The
dispersionwas stirred for 4 h and then storedovernight at 4 °C, followed
by a ﬁltration through a 1.2 μm pore size hydrophilic cellulose acetate
ﬁlter (Minisart).
2.2. Incorporation of the photosensitizers TPPS4, TPCC4 or Ce6 into the
nanogels
Water and 0.1 N HCl were added to the nanogel dispersion to
obtain a 0.07% content of nanogels (dry residue) and a pH 3.0
formulation. The photosensitizers were dissolved in water at a
concentration of 0.014% w/v for Ce6 (Frontier Scientiﬁc, Logan, UT,
USA) and 0.018% w/v for TPCC4 (Porphyrin Systems, Lübeck, Ger-
many) and TPPS4 (Sigma-Aldrich). The pH was adjusted to pH 7.0 and
the solution was ﬁltered through 0.2 μmmicroﬁlters (Minisart). Then,the photosensitizer solution was added slowly and drop-wise to the
nanogel dispersion under constant stirring to obtain a ﬁnal volume
ratio of 1:1.75 volumes of nanogels formulation to photosensitizers.
Stirring was continued for 2 h prior to the surface decoration process.2.3. Surface decoration of the photensitizer-nanogels
Fifteen mL of either TPPS4-, TPCC4- or Ce6-nanogels were added
drop-wise to 15 mLof a 0.05%w/w solution of hyaluronate (molarmass
approx. 200,000 g/mol, Lifecore, Chaska, MN, USA) or rhodamine-
tagged (cf below) hyaluronate under constant stirring. Then the pHwas
adjusted to 7.2 and stirring was continued for 2 h at room temperature.
The dispersions were stored at 4 °C for at least 16 h before use. Prior to
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hydrophilic ﬁlter (Minisart) to remove aggregates and ensure a
formulation of particles of approximately b1 μm in diameter.
2.4. Physical characterization of the nanogels
For scanning electron miscopy (SEM) the nanogels were ﬁltered
through a 30,000 g/mol Nanosep membrane (Pall, Basel, Switzerland).
The ﬁlter membrane was dried at 37 °C followed by a platinum
sputtering. The SEM images were obtained in a Zeiss Ultra 55 electron
microscopeat2 kV (Zeiss,Oberkochen,Germany). The sizedistributions
of the nanoparticles were determined from the SEM pictures. The
surface charge of the nanogel formulations was analyzed by measuring
the electrophoretic mobility in a Malvern Nanosizer (Malvern Ltd,
Malvern, UK) and expressed as zeta potential. Surface-decorated
nanogel dispersions were set to a pH of 7.4 and physiological NaCl
concentration (0. 9% w/v) prior to measurements by mixing equivalent
volumes of nanogel formulation and 1.8%w/w aqueous NaCl solution in
20 mMphosphate buffer pH 7.4, followed by ﬁltration through a 0.8 μm
hydrophilic ﬁlter (Minisart).
2.5. Preparation of the ﬂuorescein-chitosan and rhodamine-hyaluronate
nanogels
All chemicals were purchased from Sigma-Aldrich and used
without further puriﬁcation. Carboxyﬂuorescein was covalently
bound to chitosan by an amide linkage between one of the chitosan
amine functions and the carboxyﬂuorescein carboxylic acid function
using carbodiimide chemistry. In detail, 5(6)-carboxyﬂuorescein was
dispersed in water and 1% NaOH added until dissolution, then water
was added to a ﬁnal volume of 2 ml and a ﬁnal concentration of 0.38%.
To this solution, 1 mL of 3% sulfo-N-hydroxysuccinimide (sulfo-NHS)
and of 0.4% EDC⁎HCl was added. After 25 min at room temperature,
chitosan (3.45 mL, 1.16%) was added. The reaction mixture was
stirred at room temperature overnight, then dialyzed (Spectra/Por
Biotech Cellulose Ester Dialysis Membrane MWCO: 25,000 Spectrum
Ls Europe B.V., Breda, The Netherlands) against demineralized water.
The retentate was recovered by freeze drying and washed with
acetone until no ﬂuorescein absorbance could be recorded in the
acetone.
N-Boc-ethylenediamine was ﬁrst covalently bound to hyaluronate
by an amide linkage between one of the hyaluronate carboxylic acid
functions and the N-Boc-ethylenediamine amine function using
carbodiimide chemistry. Then Rhodamine B isothiocyanate (RITC)
was covalently linked via a thiourea linkage. In detail, sodium
hyaluronate was dissolved at 3% in 2 mL water. To this solution
1 mL of 3% sulfo-NHS and of 0.29% EDC⁎HCl was added. After 25 min
at room temperature, N-Boc-ethylenediamine (2.4 mg in 2 mL H2O)
was added. The reaction mixture was stirred at room temperature
overnight, then dialyzed (Spectra/Por, MWCO: 100,000) against
demineralized water. The retentate was recovered by freeze drying.
To remove the Boc protecting group, triﬂuoroacetic acid (TFA) was
added to the solid product and stirred for 40 min. TFA was then
evaporated under a nitrogen stream and the product was freeze-
dried. The solid was dissolved at 0.2% in 10 mL of a fresh 0.1 M
carbonate buffer, pH 9. To this solution, 2 mL RITC solution in
dimethyl sulfoxide (1.4 mg/mL) were added drop-wise. The reaction
mixture was left at 4 °C overnight, then dialyzed (Spectra/Por MWCO:
100,000) against demineralized water. The retentate was recovered
by freeze drying and washed with 2-propanol until no rhodamine
absorbance could be recorded in 2-propanol.
2.6. Cells
The adherent RAW 264.7 murine macrophages, L929 and NIH-3T3
ﬁbroblasts and non-adherent human THP-1 phagocytic macrophage-like monocytic leukemia cells were obtained from the ATCC
(American Tissue Culture Collection, Manassas, Virginia, USA). All
cell culture reagents were obtained from Gibco (Basel, Switzerland).
RAW 264.7 and THP-1 macrophages were grown in DMEM medium
containing 4.5 g/L glucose, 10% heat-inactivated fetal calf serum (FCS)
and penicillin/streptomycin. L929 and NIH-3T3 ﬁbroblasts were
grown in DMEM medium containing 1 g/L glucose, 10% FCS and
penicillin/streptomycin.2.7. Determination of cytotoxicity
The RAW 264.7, L929 and NIH-3T3 cells were grown in 48-well cell
culture plates (Corning, NY, USA) until 75% conﬂuent. The culture media
were replaced with fresh medium containing nanogels diluted in
complete medium and the cells were exposed to the nanogels for 24 h.
Then, medium was replaced with complete medium without nanogels
and the cell viability was evaluated using the MTT assay, essentially as
previously described [31]. Brieﬂy, MTT (3-(4,5-dimethyl-2-thiazoyl)-2,5-
diphenyltetrazolium bromide, Roche, Mannheim, Germany, 250 μg/mL
ﬁnal concentration) was added to the cells for 2 h, then the cell culture
supernatantswere removed, the cell layerswere dissolved in 2-propanol/
0.04 N HCl and absorbance at 540 nm was measured (iEMS Reader MF,
Labsystems, Bioconcept, Switzerland) and compared to the values of
control cells incubated without nanogels. Alternatively for non-adherent
human THP-1 macrophages, the alamarBlue assay was performed, as
previously described [31]. Brieﬂy, cells were exposed to 10% Alamar Blue
(Serotec, Düsseldorf, Germany) added to the cell culture medium and
ﬂuorescence increase was directly measured in a multiwell ﬂuorescence
reader (λex/λem=530 nm/580 nm) after 2 h at 37 °C.2.8. Evaluation of cell uptake of Ce6-nanogels
Cells were grown in 48-well cell culture plates (Corning) until 75%
conﬂuent. The culture medium was replaced with fresh medium
containing Ce6-nanogels diluted at 14% (v/v, ﬁnal concentration) in
complete medium and the cells were exposed to the nanogels for
various periods of time. Then, the cells were washedwith PBS and Ce6
ﬂuorescencewasmeasured in a thermostated ﬂuorescencemultiwell-
plate reader (Cytoﬂuor, PerSeptive BioSystems, Framingham, MA,
USA), at λex/λem=405/645 nm, respectively. THP-1 cells were grown
in 6-well cell culture plates (Corning) until reaching 106 cell/mL.
Then, 17% (v/v, ﬁnal concentration) of Ce6-nanogel were added to cell
medium and cells were exposed to the nanogels for various periods of
time. Cells were centrifuged at 100 g for 5 min, washed with PBS and
resuspended in 0.5 mL MeOH followed by ultra-sound treatment for
3 min. The suspension was centrifuged at 6000 g for 5 min and the
Ce6 ﬂuorescence of the supernantant was measured in a spectroﬂu-
orometer (LS50, PerkinElmer) at the Ce6-speciﬁc λex/λem=409 nm/
645 nm, respectively.2.9. Fluorescence microscopy
Cells were grown on histological slides in complete medium until
25% conﬂuent and exposed to nanogels overnight in the dark. At the
end of the incubation period, slides were washed in PBS and nuclei
were stained with 4′,6′-diamidino-2-phenylindolylhydrochloride
(DAPI, Roche Diagnostics) in PBS as previously described [32]. Then
slides were mounted in PBS and analyzed, essentially as previously
described [32], under a ﬂuorescence microscope (Axioplan2, Carl
Zeiss, Feldbach, Switzerland) with ﬁlters set at 365±5 nm excitation
light (BP 365/12, FT 395, LP 397) for DAPI, 470±20 nm (BP 450–490,
FT 510, BP 515–565) for carboxyﬂuorescein and 535±25 nm
excitation light (BP 510–560, FT 580, LP 590) for photosensitizers
and rhodamine isothiocyanate.
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Cell NO production was determined as nitrite accumulation in cell
culturemedia using the Griessmicroassay, as previously described [33].
Brieﬂy, 100 µL of cell supernatantswasadded to 100 µLofGriess reagent
(0.5% w/w sulfanilamide and 0.05% w/w naphthylethylenediamine in
2.5% w/w phosphoric acid). Absorbance was measured at 540 nm in a
multiwell-plate reader (iEMS Reader MF) and NO concentration was
calculated by comparison with a standard sodium nitrite solution.
Positive control of cell activation was obtained by incubating cells with
γIFN (100 U/mL, Roche Diagnostics) and TNF-α (400 U/mL, Roche
Diagnostics) under the same experimental conditions as the nanogels.
2.11. Determination of phototoxicity
Cells were grown in triplicate wells in 96-well cell culture plates
(Corning) until 75% conﬂuent. The culture media were replaced with
fresh medium containing the PS-nanogels diluted at 17% (v/v, ﬁnal
concentration) in complete culture medium and the cells were
exposed to the nanogels overnight. Then, the media were replaced
with DMEM without phenol red containing 5% FCS and the cell layers
were irradiated at 652 nm using a diode laser (Ceralas 652, Biolitec,
Germany) coupled to a frontal diffuser (Medlight SA, Ecublens,
Switzerland), at an irradiance of 20 mW/cm2 and light doses from
0.5 to 15 J/cm2, essentially as previously described [32,34]. Cell
viability was evaluated 24 h later using the MTT assay. Values were
compared to the values of control cells incubated without laser
irradiation.
To determine the time-course of phototoxicity, cells were grown in
96-well cell culture plates (Corning) until 75% conﬂuent. The culture
medium was replaced with fresh medium containing PS-nanogels
diluted at 17% or 8% v/v in completemediumand the cells were exposed
to the PS-nanogels for up to 24 h. At deﬁned times after PS-nanogel
addition, the media were replaced with DMEM without phenol red
containing 5% FCS and cellswere irradiated at 652 nmwith an irradiance
of 20 mW/cm2 and a light dose of 2 J/cm2. Cell viability was evaluated
24 h later using the MTT assay. Values were compared to the values of
control cells incubatedwithout laser irradiation. THP-1 cellswere grown
in 6-well cell culture plates (Corning) until reaching 6.105 cell/mL. Then,
7% (v/v, ﬁnal concentration) of Ce6-nanogel were added to the culture
medium and the cells were incubated overnight. Then, the cell
suspension was centrifuged at 100 g for 5 min, the cell pellets were
resuspended in the same volume of medium without phenol red
containing 5% FCS and the suspension was pipeted into triplicate wells
of a 96-well plate (Corning) and irradiated at 652 nmwith an irradiance
of 20 mW/cm2 and light doses up from 2 to 15 J/cm2. Cell viability was
evaluated using the alamarBlue assay. Brieﬂy, 24 h after irradiation,
Alamar Blue solution (10% ﬁnal concentration, Serotec, Düsseldorf,
Germany) was added to the cell culture medium without medium
change and ﬂuorescence increase was recorded 2 h later at 37 °C in a
ﬂuorescence microplate reader (Cytoﬂuor, PerSeptive BioSystems) at
λex/λem=530 nm/580 nm, respectively. Values were compared to the
values of control cells incubated without laser irradiation.
2.12. Murine model of antigen-induced arthritis (AIA)
Male C57BL/6 mice were obtained from Charles River (L'Arbresle,
France). All mice were housed under conventional conditions, and
water and standard laboratory chow were provided ad libitum. All
animal experiments were performed following International and
National Animal Ethics guidelines and were approved by the Animal
Ethics Committee of the Canton de Vaud, Switzerland (permit No
1876). AIA was induced essentially as previously described [35].
Brieﬂy, 8 week-old anesthetized mice were immunized at days 0 and
7 by intradermal injection at the base of the tail of an emulsion of
100 μg methylated bovine serum albumin (mBSA) (Fluka, Buchs,Switzerland) in 50 μL sterile PBS and 50 μL complete Freund's
adjuvant mixed with 200 μg Mycobacterium tuberculosis (Difco
Laboratories Inc., Franklin Lakes, NJ, USA). At day 0 mice were also
injected intraperitoneally with 2.109 heat-killed Bordetella pertussis
(Berna, Bern, Switzerland) in 0.5 mL of serile PBS. At day 21, AIA was
induced by intra-articular injection of 100 μg of mBSA in 10 μL sterile
PBS into the joint of the right knee of mice, the left knee being injected
with sterile PBS alone.
2.13. Evaluation of photosensitizer ﬂuorescence in the knees of mice
At day 23, under anesthesia, a small cut in the skin of the kneeswas
done in order to localize the site of injection of the nanogels in the
small synovial cavity of the mice and 10 μL of either TPSS4-nanogels
were injected into the treated knees (right knee), or 10 μL of PBS in
the control knees (left knee) of the same animal. The residual
ﬂuorescence of nanogels was evaluated at different times after
injection using a detection ﬂuorescence imaging system using a
modiﬁed 300 W D-light source (Xe arc lamp from Storz, Tuttlingen,
Germany) equipped with a red bandpass ﬁlter (635 nm, 20 nm
FWHM; Chroma, USA), coupled to a Storz 4 mm diameter light guide.
The output of this light guide was directed to the mice knee with a
projection objective (Nikon, Japan; AF Nikkor; 1:1.4 D/50 mm) to
generate a 2.5 cm diameter homogenous spot with an irradiance of
2 mW/cm2 at 635 nm. The ﬂuorescence was collected by another
objective (Fujinon, Japan; TV zoom lens; 1:1.2/12.5–75 mm; Type
H6X12.5R-MD3) through a longpass ﬁlter rejecting light below
665 nm (Schott, Germany; RG665) and the image was detected by a
CCD camera (752×582 pixels CF 8/1 Kappa, Gleichen, Germany)
equipped with an image intensiﬁer (Proxiﬁer BV 256-2FcZ-CH,
Proxitronic, Bensheim, Germany). The images were captured by the
8-bits camera frame grabber and saved on the computer with the
“Kappa Imagebase-control” software. Image treatment was carried
out using the IPLab imaging software and the intensities of
ﬂuorescence were evaluated using the ImageJ software.
2.14. Photodynamic treatment of mice knees
At day 23, under anesthesia, the skin of the mice knees was cut
open and injection of the Ce6-nanogel (10 μL/knee) was performed
into the arthritic knee. Irradiation was performed 2.5 h later at
652 nm using a diode laser (Ceralas 652 from Biolitec, Bonn,
Germany) coupled to a frontal diffuser (FD1 from Medlight, Ecublens,
Switzerland), at an irradiance of 50 mW/cm2 and increasing light
doses from 3.3 to 25 J/cm2. As controls for treatment efﬁcacy two
groups of mice were injected with either 25 μg of methylprednisolone
acetate (Depo-medrol, Pﬁzer), a standard therapeutic agent for the
treatment of RA in human patients, or PBS, respectively.
2.15. Evaluation of Serum Amyloid A (SAA)
Blood (0.2 mL) was taken from mice eight days after irradiation,
centrifuged, stored as aliquots at −80 °C. Serum levels of SAA were
determined using an ELISA assay (Biosource-Invitrogen, Camarillo,
California) according to themanufacturer's protocol. Means±sdwere
calculated.
2.16. Statistical analysis
Means±standard deviation were calculated and Student's t-test
was used for evaluation of statistical signiﬁcance.
3. Results
In this study we deﬁne the nanogels as colloidal system of
aggregates in the sub-micrometer range prepared from hydrophilic
Table 1
Zeta (ζ) potentials of the nanogels.
Nanogel type ζ potential [mV]
Ce6-nanogel −48
TPCC4-nanogel −39
TPPS4-nanogel −41
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micrometer range. Using the formulation of the chitosan–TPP–
photosensitizer core as described resulted in nanogel preparation
where only traces of uncomplexed chitosan and no detectable amount
of photosensitizer were found in the dispersant, thus not requiring
further puriﬁcation. The encapsulation of the anionic photosensitizers
(chemical structures shown in Fig. 1)) into hydrogels composed of
chitosan and penta sodium triphosphate (PSTP) was based on
electrostatic interaction yielding positively-charged photosensitizer-
containing nanogels (PS–nanogels). To obtain negatively charged
nanogels, the surface of the chitosan nanogels was decorated with
hyaluronate. As expected, comparable negative ζ-potential values
were obtained for all PS-nanogels (Table 1).
The size of the nanogels was estimated by scanning electron
microscopy (SEM) of the dried nanogel dispersions. The determina-
tion of nanogel size by SEM under a dry state does not result in an
accurate absolute value of the hydrated nanogel size in dispersion, but
only visualizes size range and particle shape. The SEM picture of
chlorine e6 (Ce6)-nanogels is shown in Fig. 2A. SEM analyses
conﬁrmed the relatively broad size distribution of the PS-nanogels,Fig. 2. Scanning electron microscopy (SEM) image of Ce6-hyaluronate-chitosan nanogels.
A. The Ce6-nanogel dispersion was ﬁltered through a 30,000 g/mol ﬁlter, the ﬁlter was
dried at 37 °C and platinum sputtering followed prior to SEM imaging. B. The size
distribution of the Ce6-nanogels was determined from the SEM picture.ranging from about 40 to 140 nm (Fig. 2B). The picture illustrates that
the nanogel surface is smooth and regular.
The PS-nanogelswere investigated in vitro aspotential drug-delivery
system for macrophages by evaluating their effect on the adherent
murineRAW264.7 andnon-adherent humanTHP-1macrophages. First,
the cytotoxic potential of the three PS-nanogels in the absence of a
photodynamic protocol was investigated in RAW 264.7 macrophages
exposed for 24 h to increasing concentrations of PS-nanogels using a
MTT cell survival assay (Fig. 3A). TPPS4- and TPCC4-nanogels were
not cytotoxic in the dark at all concentrations tested while a cytotoxic
effect appeared for Ce6-nanogels for a concentration N20%. For further
experiments, a 17% concentration was chosen as the maximal
concentration to avoid intrinsic cytotoxic effect of Ce6-nanogels. In
human THP-1macrophages, the increase in cell-associatedﬂuorescence
was a rapid event, and the maximal uptake was observed 3 h after
addition of the PS-nanogels, followed by a phase of saturation of the
uptake (Fig. 3B).
In order to determine whether exposure to these PS-nanogels may
result in macrophage activation, the production of nitric oxide (NO)
production, a very sensitivemarker of activation of rodentmacrophages
[33], was determined. To control for RAW 264.7 macrophage respon-
siveness to activation, cells were exposed to γIFN and TNF-α [33].
Macrophage secretion of NO was evaluated after 24 h cell exposure to
any of the three PS-nanogels (17%). None of the three PS-nanogels
induced the production of NO by RAW 264.7 murine macrophages,
whereas these cells responded to exposure to γIFN and TNF-α (Fig. 4).
Then the efﬁcacy of PS-nanogels in photodynamic therapy
protocols was determined. RAW 264.7 macrophages were exposed
for 24 h to the PS-nanogels (17%), then to 652 nm light, with an
irradiance of 20 mW/cm2 and doses ranging from 0.5 to 15 J/cm2 and
cell survival was determined using the MTT assay 24 h afterFig. 3. Interactions of Ce6-nanogels with macrophages. A. Effect of PS-nanogel
concentration on the survival of murine macrophages. RAW 264.7 macrophages
were exposed for 24 h in the dark to PS-nanogels. RAW 264.7 cell survival was
assessed using the MTT assay at the end of the incubation period. ○: TPCC4-nanogels;
■: TPPS4-nanogels; △: Ce6-nanogels. B. Time-dependent uptake of Ce6-nanogels by
human THP-1 macrophages. Ce6-nanogels were diluted at 16% (v/v) in culture medium
and added to THP-1 macrophages for increasing periods of time. Uptake was quantiﬁed
by the Ce6-speciﬁc ﬂuorescence.
Fig. 4. Nitric oxide (NO) production by murine macrophages exposed to PS-nanogels.
RAW 264.7 macrophages were exposed for 24 h to Ce6-, TPCC4- or TPPS4-nanogels
(NG) diluted at 17% (v/v) in culture medium. The production of NO by cells activated
with γIFN (100 U/mL) and TNF-α (400 U/mL) is shown for comparison.
Fig. 6. Time-dependent photodynamic efﬁcacy of Ce6-nanogels in RAW 264.7 murine
macrophages. RAW 264.7 macrophages were exposed to Ce6-nanogels diluted at 8% or
17% (v/v) in culture medium for increasing incubation times and irradiated at 1 J/cm2
dose of light at 652 nm and 20 mW/cm2. Survival was assessed 24 h after irradiation
using the MTT assay. ◊: no nanogels; △: 17% Ce6-nanogels; □: 8% Ce6-nanogels.
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Ecompletion of the irradiation (Fig. 5A). Cells treated with the
same concentration of the PS-nanogels but kept in the dark were
used as controls for dark toxicity, whereas cells which were not
exposed to PS-nanogels but exposed to light were used as controls for
laser light cytotoxicity. Untreated cells were not photosensitive in the
absence of PS-nanogels, and PS-nanogels were not cytotoxic in the
absence of light exposure. Phototoxicity responses for the three
different PS-nanogels exhibited very different patterns of efﬁciency.
For the Ce6-nanogels, the light dose which induced 50% of cell
mortality (LD50) was b0.5 J/cm2, whereas the LD50 in cells exposed toFig. 5. Photodynamic efﬁcacy of PS-nanogels in RAW 264.7 murine and THP-1
human macrophages. A. RAW 264.7 macrophages were exposed for 24 h to Ce6-,
TPCC4- or TPPS4-nanogels diluted at 17% (v/v) in culture medium prior to irradiation by
increasing doses of light at 652 nm. Cell survival was assessed 24 h later using the MTT
assay. ◊: no nanogels;□: TPPS4-nanogels;△: Ce6-nanogels;○: TPCC4-nanogels. B. Human
THP-1 macrophages were exposed for 24 h to Ce6-nanogels diluted at 7% (v/v) in culture
medium prior to irradiation by increasing doses of light at 652 nm. Cell survival was
assessed 24 h later using the alamarBlue assay. ▲: cells exposed to Ce6-nanogel; ◊: no
nanogels.TPCC4-nanogels or TPPS4-nanogels were 2 J/cm2 and 12 J/cm2,
respectively.
Human THP-1 macrophages were exposed to 7% Ce6-nanogels for
24 h, then exposed at 20 mW/cm2 and light doses increasing from 2.5
to 15 J/cm2. Cell survival was determined 24 h after the completion of
the irradiation (Fig. 5B). THP-1 cells treated with the same
concentration of the Ce6-nanogels but kept in the dark were used
as controls for Ce6-nanogel dark toxicity. Untreated THP-1 macro-
phages were not photosensitive in the absence of PS-nanogels. For
THP-1 macrophages exposed to Ce6-nanogels the LD50 was ∼2 J/cm2.
Cell irradiation in the absence of photosensitizer and/or nanogel
demonstrated absence of cytotoxicity using the MTT test and PDT
protocols performed in cells exposed to non-encapsulated photo-
sensitizers demonstrated phototoxicity (results not shown).
Detailed time-course of phototoxic efﬁcacy of Ce6-nanogels was
performed on RAW 264.7 cells exposed to 2 different concentrations of
Ce6-nanogels (8% and 17%) from 30 min to 24 h. At the end of the
exposure period, cells were irradiated at 1 J/cm2, culture was continued
and the MTT survival assay was performed 24 h later. The phototoxic
effect occurred very rapidly since efﬁcacy was already apparent 30 min
after cell exposure to the Ce6-nanogel. Less than 25% of cell survivalwas
observed after 3 h of exposure to Ce6-nanogels (Fig. 6).
As control for macrophage selectivity, the time-dependent uptake
of the Ce6-nanogels was monitored between 30 min and 24 h in
RAW264.7murinemacrophages and comparedwith L929 or NIH-3T3
murine ﬁbroblasts (Fig. 7). The increase in cell-associated ﬂuores-
cence in murine RAW 264.7 macrophages was a rapid event, and the
maximal uptake was observed after 4 h of exposure, followed byFig. 7. Time-dependent uptake of Ce6-nanogels by murine macrophages and ﬁbroblasts.
Ce6-nanogels were diluted at 14% v/v in culture medium and added to RAW 264.7
macrophages, L929 or NIH-3T3 murine ﬁbroblasts for increasing period of time. Uptake
of Ce6 nanogels was quantiﬁed by the Ce6-speciﬁc ﬂuorescence. ○: RAW 264.7
macrophages ; □: L929 ﬁbroblasts; △: NIH- 3T3 ﬁbroblasts.
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ﬁbroblasts, no uptake of Ce6-nanogels was observed.
The uptake and intracellular localization of Ce6-nanogels in
RAW 264.7 macrophages was conﬁrmed by ﬂuorescence microscopy
(Fig. 8A), using the Ce6-associated red ﬂuorescence as a reporter
and DAPI labeling (blue) of the cell nuclei. The Ce6-associated
ﬂuorescence was found in the cell cytoplasm as red ﬂuorescent
spots. No nucleus-associated ﬂuorescence was observed. Moreover,Fig. 8. Intracellular accumulation of photosensitizer and nanogel polymers in murine
macrophages. A. RAW264.7 macrophages were incubated overnight in the dark without
(a) and with (b) Ce6-nanogels (15%, v/v) and nuclei were counterstained with DAPI.
The cell uptake and localization of Ce6 and DAPI were analyzed by ﬂuorescence
microscopy. Ce6 and DAPI appear as red and blue ﬂuorescence, respectively. B. Cells
were incubated overnight in the dark with 15% (v/v) nanogels composed of
carboxyﬂuorescein-chitosan (CF) and rhodamine isothiocyanate-hyaluronate (RITC).
Nuclei were counterstained with DAPI. The cell uptake and localization of DAPI, CF and
RITC were analyzed by ﬂuorescence microscopy. Fluorescence images of DAPI, CF and
RITC are respectively represented in a, b, c while the merged images are shown in d.
Scale bars represent 20 μm in all pictures.no nuclear fragmentation, a marker of cell apoptosis, was observed
conﬁrming the absence of cell toxicity in the absence of light
exposure. Comparable information was obtained with TPPS4- and
TPCC4-nanogels (results not shown). In order to determine whether
the polymer components, chitosan and hyaluronate, forming the
nanogels were also internalized by cells, chitosan was labeled with
carboxyﬂuorescein (green ﬂuorescence) and hyaluronate with rho-
damine (red ﬂuorescence) in nanogels not loaded with photosensi-
tizer. RAW 264.7 macrophages were exposed to these PS-empty,
ﬂuorescence-tagged nanogels. The ﬂuorescence associated to the two
polymers was found co-localized in the cytoplasm of the cells
(Fig. 8B). Again, no nuclear localization of the polymers was observed
in the DAPI blue-ﬂuorescent nuclei.
The photosensitizer-loaded nanogels were investigated in vivo as a
potential photosensitizer delivery system for the photodynamic
therapy of inﬂammatory diseases of articular joints using the murine
model of antigen-induced arthritis (AIA). First, TPPS4-nanogels were
injected in normal mice knees and the clearance of the photosensi-
tizer was evaluate by its associated ﬂuorescence in the knees and
compared to the clearance of free photosensitizer. The results showed
that the ﬂuorescence was retained much longer in the normal knees
when the photosensitizer was injected as a nanogel compared to free
photosensitizer (Fig. 9A). Then Ce6-nanogels were injected either in
the normal knee or the arthritic knee of AIA mice. The Ce6-associated
ﬂuorescence was retained longer in arthritic knees compared to
normal knees (Fig. 9B).
Then, the nanogels were evaluated in AIA mice as a potential
photodynamic treatment for rheumatoid arthritis. Ce6-nanogels were
injected in the arthritic knee of AIA mice and the knee was exposed 2 hFig. 9. Retention of photosensitizers in mice knees as free drugs or as nanogels.
A. Fluorescence of the TPPS4 photosensitizer injected in normal mice knee. TPPS4 was
injected in the mice knees as TPPS4-nanogels (■) or as free molecule (△).
B. Fluorescence of the Ce6-nanogels injected in mice knee. Ce6 nanogels were injected
in normal (△) or arthritic knee from AIA mice (■). Insert. Representative Ce6
ﬂuorescence image 1 h after injection of Ce6-nanogels in arthritic knee.
Fig. 10. SerumAmyloid A (SAA) levels. Circulating levels of SAAwere determinedeightdays
after injection in themice knees (number ofmice≥7) of either Ce6-nanogels (Ce6-NG) or
methylprednisolone and photodynamic treatment protocol. An unpaired Student's t-test
was used for evaluation of statistical signiﬁcance. For each group, n≥7. *: pN0.05.
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with light doses from 3.3 to 25 J/cm2. Eight days after irradiation, blood
samples were taken from treated mice and the serum levels of Serum
Amyloid A (SAA), an acute-phase protein, was quantiﬁed as reporter of
inﬂammation (Fig. 10). Results showed that the SAA levels decreased
strongly after the treatment at 25 J/cm2, reaching values comparable to
the values measured after the injection of prednisolone, a standard
corticoid treatment used in clinic for the treatment of rheumatoid joints.4. Discussion
In the study presented here, chitosan-based nanogels whose
surface was decorated with hyaluronate and incorporating amphi-
philic photoactive molecules were prepared. The formation of the
nanogels composed of chitosan, penta sodium triphosphate and one
anionic photosensitizer was primarily based on electrostatic interac-
tions yielding hydrogels. The tetrapyrolic ring and the side chains
bearing carboxylate or sulfonate moieties of the photosenzitizers
chosen allowed their entrapment into the positively-charged chitosan
core of the nanogels. The advantages of decorating the nanogels with
hyaluronate were multiple: the positive charge of chitosan is inverted
to negative charge, thus favouring biocompatibility, hyaluronate has
the potential to target the CD44 cell surface receptor of macrophages
which is involved in phagocytosis [36,37] and is overexpressed in the
activated macrophages. Thus hyaluronate decoration of nanogels
improved both selectivity and uptake of nanogels by the macro-
phages. Moreover, as intraarticular injection of hyaluronate has
beneﬁcial effects in patients with rheumatoid arthritis [38], the
presence of hyaluronate at the surface of the nanogels in inﬂamed
joints will not further enhance inﬂammation.
Using murine and human macrophages we demonstrated that
these chitosan-based nanogels can deliver photosensitizers to
macrophages, then allowing effective PDT protocols to be performed.
Murine ﬁbroblasts used as control cells of a non-macrophage origin
did not take up these PS-nanogels. In an arthritic knee, many cells
including immune cells and synoviocytes are activated/stimulated by
bacterial products and cytokines. Under these conditions, synovio-
cytes would behave in part as macrophages. We used ﬁbroblasts not
as a model for activated/stimulated synoviocytes, but as a model of
non-activated cells, to determine whether this type of resting cells
would also be affected by the PS-nanogels, and exclude generalized
inﬂammatory or unspeciﬁc effects of the PS-nanogels. The polymers
used to form the nanogels are known as biocompatible [26]. In
agreement with this information, we did not observe any cytotoxicity
in the absence of light exposure, even at very high level of cell
exposure to the PS-nanogels. Only the Ce6-nanogels were slightly
cytotoxic at high concentration, due to the known intrinsic cytotoxi-
city of this photosensitizer. The cell uptake of such PS-nanogels wasvery rapid (b4 h) and the ﬂuorescence associated with the photo-
sensitizer was retained inside cells for up to 24 h. Fluorescence
microscopy studies demonstrated that the photosensitizer and the
two polymers forming the nanogels were taken up by the macro-
phages and concentrated in cell cytoplasm and organelles, but not in
the nucleus. A delivery system, which targets inﬂammatory diseases,
must not over-activate the target cells. NO is a key factor secreted at
high levels by activated rodent macrophages. The demonstrated
absence of secretion of NO by murine macrophages incubated with
the PS-nanogels conﬁrmed this important property of the nanogels.
Comparable information had been previously obtained using other
types of nanoparticles, including dextran-coated ultrasmall super-
paramagnetic iron oxide (USPIO) nanoparticles used in clinics as MRI
contrast agents [39].
Singlet oxygen, which is the cytotoxic entity formed during the
photodynamic treatment, is produced in very close proximity of the
photosensitizer and has a very short half-life in aqueous media.
Therefore, achieving intracellular uptake of photosensitizers is
necessary for good phototoxic efﬁcacy. The photosensitizer encapsu-
lated in the nanogels achieved good photodynamic efﬁciency
displaying LD50 values comprised between b0.5 J/cm2, 2 J/cm2 or
12 J/cm2, respectively, dependent on the particular photosensitizer.
As no signiﬁcant differences in the uptake of the three PS-nanogels by
macrophages were observed, these results are compatible with the
known hierarchy of intrinsic photodynamic efﬁciencies of the three
photosensitizers. It has to be noted that light doses of 1–15 J/cm2 and
up to 48 J/cm2 are generally used in most photodynamic therapy
protocols [33,34,40–43].
The antigen-induced arthritis (AIA) model of rheumatoid arthritis
(RA) recapitulates features of human RA [44,45]. This model is based
on a T cell-mediated joint inﬂammation. PDT protocols have been
previously evaluated in models of RA [8–12], using various photo-
sensitizers in several animal models of AIA. The photosensitizers
BPDMA, mTHPC or 5-aminolevulinic acid hexyl ester were also
evaluated in murine models of AIA with beneﬁcial effects [10–12]. In
our approach, the efﬁciency of photodynamic treatment of mice
knees was evaluated by measuring the concentration in mice blood of
the Serum Amyloid A (SAA), an acute-phase protein which is used in
the diagnosis and prognosis of human adult RA and AIA models
[13,14,45,46]. SAA measurements in the blood, when compared to
histological examination of slides of the knees at the end of the
experimental period, allow to follow the time-course of response to
treatment. In addition, SAA measurement allows to obtain more
objective and quantitative information than grading of histological
slides.
The quantiﬁcation, eight days after light exposure, of the
circulating levels of SAA demonstrated the efﬁciency of the PDT
treatment at 25 J/cm2. With this PDT protocol, SAA levels after this
PDT protocol were comparable with the SAA levels obtained after
intraarticular injection of methylprednisolone, a corticoid used in the
clinic for the local treatment of RA patients.
5. Conclusion
In conclusion, the present results demonstrated that hydrophilic
chitosan-based nanogels decorated with hyaluronate and encapsu-
lating photosensitizers are excellent drug-delivery systems for the
selective delivery of photosensitizers to macrophages and photody-
namic destruction of these cells. This nanogel delivery system was
also efﬁcient in vivo for increasing the retention and decreasing the
clearance of photosensitizers from the inﬂammed leaky articular
joints in a murine modeld of rheumatoid arthritis, This nanogel
system also allowed efﬁcient PDT protocols to be performed in vivo.
Therefore beneﬁt can be expected in using such a delivery system to
treat inﬂamed articular joint not only for photosensitizers and PDT
protocols, but also for other chemotherapeutics.
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